PracticeUpdate: Oncology - Winter 2018

CONTENTS 5

COVER 7

RESEARCH Editor’s picks 7 Adjuvant Chemotherapy Guided by a

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer Comment by Lee S Schwartzberg MD

21-Gene Expression Assay in Breast Cancer Comment by Lee S Schwartzberg MD

8 Ribociclib Plus Endocrine Therapy for

Premenopausal Women With HR+ Advanced Breast Cancer Comment by Reshma L Mahtani DO

EXPERT OPINIONS 20 10 Practice Changes That I Will Make After Attending ASCO 2018 By Jeffrey J Kirshner MD

9 Pembrolizumab vs Paclitaxel for Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer Comment by Axel Grothey MD 10 Clinical Consequences of Chemotherapy Dose Reduction in Obese Patients With Stage III Colon Cancer Comment by Axel Grothey MD 11 Progression-Free Survival at 24 Months and Subsequent Outcomes for Patients With DLBCL

22 Top 3 Advances in Radiation Oncology From ASCO 2018 Interview with Helen A Shih MD by Farzanna S Haffizulla MD

CONFERENCES 24 ASCO 2018 24 Lung Cancer Studies at ASCO 2018 Interview with Wilfried Eberhardt MD by Farzanna S Haffizulla MD 25 ASCO 2018: Best in Ovarian Cancer By Annette Hasenburg Prof. Dr. med. 26 Multiple Myeloma at ASCO 2018 Interview with Rafael D Fonseca MD by Farzanna S Haffizulla MD 26 ASCO 2018: Updates on PARP Inhibitors in Prostate Cancer Interview with Neeraj Agarwal MD by Sumanta Kumar Pal MD 27 Mirtazapine Prevents Delayed Nausea and Vomiting in Highly Emetogenic Chemotherapy By the PracticeUpdate Editorial Team 28 Patients With Advanced Cancer May Not Have to Accept Anorexia as Inevitable By the PracticeUpdate Editorial Team 29 Shorter Trastuzumab Treatment for HER2- Positive Breast Cancer Can Be as Effective,

30 EHA 2018 By the PracticeUpdate Editorial Team

11 Immune Recognition of Somatic Mutations Leading to Complete Durable Regression in Metastatic Breast Cancer 12 Sunitinib Alone or After Nephrectomy in Renal Cell Carcinoma Comment by Bradley G Somer MD 13 Circulating Tumor Cell Status Predicts Radiotherapy Benefit in Early Breast Cancer Comment by Lee S Schwartzberg MD 14 Three-Month Post-Treatment PSA Level as a Biomarker of Treatment Response in Patients With Intermediate- or High-Risk Prostate Cancer Treated With ADT and RT Comment by Brian E Lewis MD 15 Male Breast Cancer: An Updated SEER Data Analysis 16 Intravesical Instillation of Gemcitabine vs Saline After Resection of Suspected Low- Grade Non-Muscle Invasive Bladder Cancer Comment by Thomas J Guzzo MD 17 Risk Stratification of Smoldering Multiple Myeloma Incorporating Revised IMWG Diagnostic Criteria 18 Efficacy and Safety of ABP 980 Compared With Reference Trastuzumab in HER2+ Early Breast Cancer

30 Consider Obinutuzumab Plus Chlorambucil for First-Line Treatment for CLL 31 Neither Myeloablative nor Reduced-Intensity Conditioning Impact Overall Survival in T-Cell Lymphoma 32 Response Rates Improve Significantly With Three-Drug Combination for DLBCL 33 EUTOS Long-Term Survival Score Superior for Prognosis of Survival in CML 34 Rituximab Yields Durable Response in Adults With Persistent or Chronic Immune Thrombocytopenia

With Fewer Cardiac Side Effects By the PracticeUpdate Editorial Team

VOL. 2 • NO. 3 • 2018